KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Idexx Laboratories (IDXX) Operating Income (2016 - 2025)

Historic Operating Income for Idexx Laboratories (IDXX) over the last 17 years, with Q3 2025 value amounting to $354.8 million.

  • Idexx Laboratories' Operating Income rose 1676.71% to $354.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 1746.11%. This contributed to the annual value of $1.1 billion for FY2024, which is 284.46% up from last year.
  • Idexx Laboratories' Operating Income amounted to $354.8 million in Q3 2025, which was up 1676.71% from $373.0 million recorded in Q2 2025.
  • Idexx Laboratories' Operating Income's 5-year high stood at $373.0 million during Q2 2025, with a 5-year trough of $179.1 million in Q2 2022.
  • In the last 5 years, Idexx Laboratories' Operating Income had a median value of $261.7 million in 2024 and averaged $268.5 million.
  • In the last 5 years, Idexx Laboratories' Operating Income skyrocketed by 7157.25% in 2021 and then tumbled by 3093.0% in 2022.
  • Idexx Laboratories' Operating Income (Quarter) stood at $199.2 million in 2021, then grew by 13.72% to $226.5 million in 2022, then increased by 8.29% to $245.3 million in 2023, then rose by 6.68% to $261.7 million in 2024, then soared by 35.6% to $354.8 million in 2025.
  • Its last three reported values are $354.8 million in Q3 2025, $373.0 million for Q2 2025, and $316.5 million during Q1 2025.